Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Osmotic demyelination syndrome.
Epperla N, Landeck J, Sabbagh S. Epperla N, et al. WMJ. 2014 Oct;113(5):197-8. WMJ. 2014. PMID: 25739163 Free article.
C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy.
Epperla N, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Calzada O, Xavier AC, Zhou Z, Hossain NM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, Evens AM, Flowers CR, Cohen JB, Fenske TS, Hamadani M, Costa LJ. Epperla N, et al. Cancer. 2017 Nov 15;123(22):4411-4418. doi: 10.1002/cncr.30895. Epub 2017 Jul 27. Cancer. 2017. PMID: 28749548 Free article.
Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease?
Vaughn JL, Zhao Q, Epperla N, Puto M, Roddy J, Elder P, Blum W, Klisovic R, Jaglowski S, Penza S, William B, Andritsos L, Brammer JE, Hofmeister C, Efebera Y, Benson D, Devine S, Cataland S, Vasu S. Vaughn JL, et al. Among authors: epperla n. Bone Marrow Transplant. 2019 Jun;54(6):913-916. doi: 10.1038/s41409-018-0390-3. Epub 2018 Nov 9. Bone Marrow Transplant. 2019. PMID: 30413812 No abstract available.
Resistance mechanism for ibrutinib in marginal zone lymphoma.
Epperla N, Shana'ah AY, Jones D, Christian BA, Ayyappan S, Maddocks K, Woyach JA. Epperla N, et al. Blood Adv. 2019 Feb 26;3(4):500-502. doi: 10.1182/bloodadvances.2018029058. Blood Adv. 2019. PMID: 30760464 Free PMC article.
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study.
Epperla N, Zhao Q, Chowdhury SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Bruno XJ, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan C, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse G. Epperla N, et al. J Hematol Oncol. 2022 Jul 16;15(1):96. doi: 10.1186/s13045-022-01316-1. J Hematol Oncol. 2022. PMID: 35842643 Free PMC article.
Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL.
Zurko J, Nizamuddin I, Epperla N, David K, Cohen JB, Moyo TK, Ollila T, Hess B, Roy I, Ferdman R, Liu J, Chowdhury SM, Romancik J, Bhansali RS, Harris EI, Sorrell M, Masel R, Kittai AS, Denlinger N, Sigmund AM, Fitzgerald L, Galvez C, Ma S, Winter J, Pro B, Gordon LI, Danilov A, Stephens D, Shah NN, Kenkre V, Barta SK, Torka P, Shouse G, Karmali R. Zurko J, et al. Among authors: epperla n. Blood Adv. 2023 Jun 27;7(12):2657-2669. doi: 10.1182/bloodadvances.2022008240. Blood Adv. 2023. PMID: 36094847 Free PMC article.
Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents.
Faisal MS, Hanel W, Voorhees T, Li R, Huang Y, Khan A, Bond D, Sawalha Y, Reneau J, Alinari L, Baiocchi R, Christian B, Maddocks K, Efebera Y, Penza S, Saad A, Brammer J, DeLima M, Jaglowski S, Epperla N. Faisal MS, et al. Among authors: epperla n. Cancer Med. 2023 Apr;12(7):8228-8237. doi: 10.1002/cam4.5631. Epub 2023 Jan 18. Cancer Med. 2023. PMID: 36653918 Free PMC article.
A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma.
Hanel W, Shindiapina P, Bond DA, Sawalha Y, Epperla N, Voorhees T, Welkie RL, Huang Y, Behbehani GK, Zhang X, McLaughlin E, Chan WK, Brammer JE, Jaglowski S, Reneau JC, Christian BA, William BM, Cohen JB, Baiocchi RA, Maddocks K, Blum KA, Alinari L. Hanel W, et al. Among authors: epperla n. Cancers (Basel). 2023 Feb 24;15(5):1437. doi: 10.3390/cancers15051437. Cancers (Basel). 2023. PMID: 36900230 Free PMC article.
Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.
Greenwell IB, Staton AD, Lee MJ, Switchenko JM, Saxe DF, Maly JJ, Blum KA, Grover NS, Mathews SP, Gordon MJ, Danilov AV, Epperla N, Fenske TS, Hamadani M, Park SI, Flowers CR, Cohen JB. Greenwell IB, et al. Among authors: epperla n. Cancer. 2018 Jun 1;124(11):2306-2315. doi: 10.1002/cncr.31328. Epub 2018 Mar 26. Cancer. 2018. PMID: 29579328 Free PMC article.
151 results